ALNFL — Nfl Biosciences SAS Share Price
Last trade - 00:00- €15.56m
- €12.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.99 | ||
| Price to Tang. Book | 5.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -130.23% | ||
| Return on Equity | -128.42% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nfl Biosciences SAS is a France-based company which provides botanical pharmaceutical services. The Company's products help cure addictions through an approach based on botanical pharmaceutical agents. It develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The Company applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- September 4th, 2006
- Public Since
- July 5th, 2021
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 7,606,769
- Address
- 199 rue Helene Boucher, CASTELNAU-LE-LEZ, 34170
- Web
- https://www.nflbiosciences.com/
- Phone
- +33 411937667
- Auditors
- Institut Fiduciaire d'Expertise Comptable
Upcoming Events for ALNFL
Similar to ALNFL
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
As of Today at 19:15 UTC, shares in Nfl Biosciences SAS are trading at €2.05. This share price information is delayed by 15 minutes.
Shares in Nfl Biosciences SAS last closed at €2.05 and the price had moved by -24.95% over the past 365 days. In terms of relative price strength the Nfl Biosciences SAS share price has underperformed the FTSE Global All Cap Index by -29.55% over the past year.
The overall consensus recommendation for Nfl Biosciences SAS is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Nfl Biosciences SAS does not currently pay a dividend.
Nfl Biosciences SAS does not currently pay a dividend.
Nfl Biosciences SAS does not currently pay a dividend.
To buy shares in Nfl Biosciences SAS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €2.05, shares in Nfl Biosciences SAS had a market capitalisation of €15.56m.
Here are the trading details for Nfl Biosciences SAS:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALNFL
Based on an overall assessment of its quality, value and momentum Nfl Biosciences SAS is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Nfl Biosciences SAS is €5.00. That is 144.5% above the last closing price of €2.05.
Analysts covering Nfl Biosciences SAS currently have a consensus Earnings Per Share (EPS) forecast of -€0.71 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nfl Biosciences SAS. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +59.11%.
As of the last closing price of €2.05, shares in Nfl Biosciences SAS were trading +0.05% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nfl Biosciences SAS PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €2.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Nfl Biosciences SAS' directors